Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) market. Most inpatients are successfully treated empirically with such agents, making it difficult for branded products like Merck & Co.’s Zerbaxa, Allergan’s Avycaz, Melinta’s Vabomere and Baxdela, Achaogen’s Zemdri, Tetraphase’s Xerava, or Paratek’s Nuzyra to gain uptake in earlier lines of therapy. However, rising antimicrobial resistance rates have created the need for safer products to effectively treat drug-resistant GNIs, and our primary market research shows that activity against key drug-resistant pathogens is an important driver of brand use in this market. Furthermore, hospital-based ID specialists report shifts in how they treat GNIs in response to the growing drug resistance.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use, so you can create specific messaging around these treatment dynamics in order to more effectively
increase or defend your market position.
GEOGRAPHIES: United States
PRIMARY RESEARCH: Survey of 100 U.S. hospital based, infectious disease and critical care specialists
KEY DRUGS COVERED: Avycaz, Zerbaxa, Vabomere, Zemdri, Xerava, Nuzyra, Baxdela, and other key GNI drugs